财务数据和关键指标变化 - 第一季度总收入增加到95.3百万美元 [32] - CAPLYTA净收入为94.7百万美元,同比增长173% [32] - 毛利率在低30%左右,预计将增加至中30%左右 [43][44] - 现金、现金等价物和投资证券总额为5.405亿美元,无债务 [37] 各条业务线数据和关键指标变化 - CAPLYTA处方量同比增长159%,环比增长16% [7][22] - 新患者启动量现已是之前的5-6倍 [23] - 处方医生数量已超过25,000名,第一季度新增近4,000名首次开具医生 [24] 各个市场数据和关键指标变化 - 双相抑郁症是一个大的市场机会,目前只有一种药物获批用于双相II型抑郁症 [27] - 抗精神病药物处方医生群体庞大,公司正在持续扩大覆盖范围 [28] 公司战略和发展方向及行业竞争 - 公司正在扩大CAPLYTA在双相抑郁症和精神分裂症适应症的开发 [8] - 正在开展三项MDD适应症的注册研究,预计2024年提交SNDA申请 [12] - 正在开发长效注射剂型,以及其他管线如PDE1抑制剂和5-HT2A受体拮抗剂 [13][14][18] - 公司有信心CAPLYTA将继续保持强劲增长 [25][26] 管理层对经营环境和未来前景的评论 - 公司对CAPLYTA的未来增长潜力充满信心 [7][20] - 对于混合特征患者的研究结果感到高兴,认为可以治疗一系列情绪障碍 [6][9] - 对管线项目的进展也感到乐观,包括长效注射剂和其他新药 [13][14][18] 问答环节重要的提问和回答 问题1 **Vardhman Chhajed 提问** 对于毛利率在未来季度的变化趋势有何预期? [42] **Larry Hineline 回答** 毛利率预计将从第一季度的低30%增加至中30%左右,主要是由于商业渠道销量增加以及商业覆盖率提高 [43][44] 问题2 **Leonid Timashev 提问** 对于混合特征患者群体,需要进行多少教育宣传才能提高医生的认知和诊治水平? [54] **Sharon Mates 和 Suresh Durgam 回答** 随着DSM-5的发布,医生对混合特征的认知已有所提高,公司也在通过发表论文、参加学术会议等方式持续教育医生群体 [55][56][57] 问题3 **Andrew Tsai 提问** 在MDD适应症的研究中,公司对于MADRS量表改善幅度有何预期? 是否会考虑将两项MDD研究的数据一起发布? [60][61] **Sharon Mates 回答** 通常MDD适应症的MADRS改善幅度在2-4分左右,公司会根据具体研究进度决定是否将数据一起发布 [61][62]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________ FORM 10-Q _______________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-36274 _______________________ INTRA-CELLULAR ...

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2022 Earnings Conference Call March 1, 2023 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder, Chairman, and CEO Mark Neumann - EVP & Chief Commercial Officer Lawrence J. Hineline - SVP, Finance and CFO Suresh Durgam - EVP & CMO Conference Call Participants Andrew Tsai - Jefferies Brian Abrahams - RBC Capital Markets Unidentified Analyst - J.P. Morgan Chase Michael DiFiore - Evercore ISI Marc Goodman - SVB ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36274 Intra-Cellular Therapies, Inc. (Exact name of registrant as specified in its charter) Delaware 36-4742850 (S ...

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Co-Founder, Chairman, CEO & President Mark Neumann - EVP & Chief Commercial Officer Lawrence Hineline - SVP, Finance, CFO, Treasurer & Assistant Secretary Suresh Durgam - EVP & Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Brian Abrahams - RBC Capital Markets Michael DiFiore - Evercore ISI A ...

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Juan Sanchez - Vice President, Corporate Communications and Investor Relations Sharon Mates - Chairman and Chief Executive Officer Mark Neumann - Executive Vice President and Chief Commercial Officer Suresh Durgam - Executive Vice President Chief Medical Officer Larry Hineline - Senior Vice President and Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Jess ...

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Juan Sanchez - Vice President, Corporate Communications and Investor Relations Sharon Mates - Chairman and Chief Executive Officer Mark Neumann - Executive Vice President and Chief Commercial Officer Suresh Durgam - Executive Vice President Chief Medical Officer Larry Hineline - Senior Vice President and Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Jessic ...

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2021 Earnings Conference Call March 1, 2022 8:30 AM ET Company Participants Juan Sanchez – Vice President-Corporate Communications and Investor Relations Sharon Mates – Chairman and Chief Executive Officer Mark Neumann – Executive Vice President and Chief Commercial Officer Larry Hineline – Senior Vice President and Chief Financial Officer Conference Call Participants Jessica Fye – JPMorgan Brian Abrahams – RBC Capital Markets Andrew Tsai – Jefferies Mike DiFi ...

Corporate Presentation February 2022 Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, our plans to commercialize CAPLYTA f ...

Corporate Presentation January 2022 Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, our plans to commercialize CAPLYTA fo ...